Retrospective13
|
Romania |
Patients under anti-TB
treatment (outcome only in retreatment group) |
55/120,132 |
0.05 |
45 |
ATIN (4), ATN (1) |
96 |
100 |
Retrospective8
|
Worldwide |
AKI after rifampin |
48/NA |
NA |
47.4 |
ATIN (4), ATN (11), crescentic GN (2) |
87 |
64 |
Retrospective16
|
India |
Rifampin-associated AKI |
25/NA |
NA |
41.6 |
ATIN (7), ATN (2), crescentic GN (1), mesangial
proliferation (3) |
100 |
80 |
Retrospective15
|
South Africa |
Biopsy-proven AIN
under anti-TB treatment |
41/NA |
NA |
42.2 |
ATIN (41) |
83 |
83 |
Retrospective14
|
Taiwan |
Patients under anti-TB
treatment |
99/1,394 |
7.1 |
68 |
NA |
73 |
11 |
Prospective (current study) |
Taiwan |
Patients under anti-TB treatment |
11/106 |
10.4 |
52.6 |
NA |
100 |
2.8 |